Management of nocturnal enuresis in Greek children.
Our experiences of managing nocturnal enuresis in Greek children at our Outpatient Clinics of Pediatric Urology are described. Between March 2001 and October 2003, 142 children with primary nocturnal enuresis (93 boys and 49 girls), aged 7-18 years old (mean: 9.0+/-0.5) were included in this prospective study. Initially, behavioral conditioning therapy, using a body-worn urinary alarm, was instructed in all cases. If no improvement was recorded, 40 microg of intranasal desmopressin was administered, initially for three months. If urodynamic studies demonstrated pure detrusor instability, anticholinergics (5 mg oxybutinine or 2 mg tolterodine) were given instead. Combination medication (desmopressin and anticholinergics) was administered for coexisting diurnal enuresis, which was present in 8 children. Among the 142 children the overall response rate was 51.41%. Successful response was recorded in 16 children practicing conditioning behavioral therapy, in 47 receiving desmopressin (with or without anticholinergics), and in 10 children receiving only anticholinergics. During the follow-up period (mean: 6.2 months), no serious side effect was recorded. The use of desmopressin, and anticholinergics in specific subgroups, was found to be effective and safe for the management of nocturnal enuresis in children.
Triantafyllidis
A
A
Department of Urology, School of Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece. artriant@otenet.gr
Charalambous
S
S
Papatsoris
A G
AG
Papathanasiou
A
A
Kalaitzis
C
C
Rombis
V
V
Touloupidis
S
S
D000281:Administration, Intranasal; D000293:Adolescent; D001521:Behavior Therapy / Q000379:methods; D002648:Child; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage*; D004775:Enuresis / Q000188:drug therapy* / Q000628:therapy; D005260:Female; D006115:Greece; D006801:Humans; D008297:Male; D011446:Prospective Studies; D012076:Renal Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome
D018680:Cholinergic Antagonists; D012076:Renal Agents; D003894:Deamino Arginine Vasopressin